-
公开(公告)号:US20120028901A1
公开(公告)日:2012-02-02
申请号:US13026070
申请日:2011-02-11
申请人: MICHAEL DOCKAL , RUDOLF HARTMANN , MARKUS FRIES , FRIEDRICH SCHEIFLINGER , HARTMUT EHRLICH , ULRICH REINEKE , FRANK OSTERKAMP , THOMAS POLAKOWSKI
发明人: MICHAEL DOCKAL , RUDOLF HARTMANN , MARKUS FRIES , FRIEDRICH SCHEIFLINGER , HARTMUT EHRLICH , ULRICH REINEKE , FRANK OSTERKAMP , THOMAS POLAKOWSKI
CPC分类号: A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
摘要: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
摘要翻译: 本发明提供了结合组织因子途径抑制剂(TFPI),包括TFPI抑制肽的肽及其组合物。 肽可以用于抑制TFPI,增强凝血因子缺陷受试者中的凝血酶形成,增加受试者中的血块形成,治疗受试者的血液凝固障碍,纯化TFPI和鉴定TFPI结合化合物。
-
公开(公告)号:US20100022445A1
公开(公告)日:2010-01-28
申请号:US12425277
申请日:2009-04-16
摘要: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
摘要翻译: 一种肽或肽衍生物,其包含:(i)WDLYFEIVW(SEQ ID NO:1); 或(ii)在WDLYFEIVW(SEQ ID NO:1)中包含一个,两个,三个或四个L-氨基酸取代的变体氨基酸序列; 或(iii)部分(i)和(ii)中任一项的肽或肽衍生物的逆转型变体,其中所述肽或肽衍生物具有促凝活性。 一种肽或肽衍生物,其包含:(i)包含成纤维细胞的氨基酸序列; 或(ii)在成纤维细胞中包含一个,两个,三个,四个,五个或六个氨基酸取代的变体氨基酸序列,其中所述肽或肽衍生物具有促凝活性。
-